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Abstract
Objective—To investigate whether prenatal atazanavir (ATV) exposure, assessed by meconium 
antiretroviral quantification, predicts early child language outcomes. Prenatal ATV exposure 
previously was associated with poorer language development in one-year-olds.
Methods—Pregnant women with HIV and their uninfected infants enrolled in the SMARTT 
study. Meconium antiretroviral concentrations were quantified by liquid chromatography-tandem 
mass spectrometry. Language development at 1 year was assessed with MacArthur-Bates 
Communicative Development Inventory (CDI) and Bayley Scales of Infant and Toddler 
Development—Third Edition (Bayley-III). Late language emergence (LLE) was defined as ≥ one 
of four CDI scores ≤10th percentile for age. Associations between fetal ATV exposure timing and 
duration, meconium ATV concentration, and language outcomes were evaluated, adjusting for 
potential confounders.
Results—Through 2013, meconium samples were available from 175 of 432 infants with 
prenatal ATV exposure. Valid Bayley-III (n=93) and CDI (n=106) assessments also were available. 
After adjustment for potential confounders, higher ATV meconium concentrations were associated 
with lower LLE risk (P=0.04), and cumulative ATV exposure duration also was associated with 
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higher Bayley-III Language scores (P=0.03). Maternal ATV duration and initiation week 
correlated with ATV meconium concentrations (positively and negatively, respectively).
Conclusions—Higher meconium ATV concentrations were protective against developmental 
language delays at 1 year, suggesting the importance of fetal ATV detoxification into meconium. 
This information supports ATV exposure safety for infant language development. ATV is a 
preferred ARV for pregnant women with HIV, suggesting the importance of ATV safety 
investigations. Additionally, further pursuit of the influences on language development in HEU 
infants is required.
Keywords
meconium; atazanavir; antiretroviral; language; HIV-exposed infants
INTRODUCTION
Antiretroviral therapy (ART) during pregnancy improves maternal health and reduces 
mother-to-child transmission of human immunodeficiency virus (HIV) to less than 2%
1
 in 
the US. Such extensive ART use during pregnancy, however, requires careful monitoring for 
potential ART toxicity in prenatal HIV-exposed uninfected (HEU) children. The protease 
inhibitor atazanavir (ATV) is a preferred ART agent in pregnancy and is becoming one of 
the most commonly prescribed antiretroviral (ARV) drugs for pregnant women with HIV.
1,2 
Recent Pediatric HIV/AIDS Cohort Study (PHACS) research demonstrated associations 
between fetal ATV exposure and poor early language development risk.
3,4 One-year-olds 
whose mothers were prescribed ATV during pregnancy had lower mean Bayley Scales of 
Infant and Toddler Development—Third Edition
23
 (Bayley-III) Language domain scores 
compared to infants without ATV exposure.
3
 In a separate investigation, prenatal ATV 
exposed one-year-olds also had increased late language emergence (LLE) risk, but language 
screening at age two showed no significant association between LLE and ATV exposure.
4 
This association of intrauterine ATV exposure and lower performance on infant language 
development measures deserves further study.
Approximately 20% of maternal ATV in blood crosses the placenta, directly exposing the 
fetus.
5
 ATV also inhibits uridine diphosphate glucuronosyltransferase (UGT) 1A1, the 
hepatic enzyme responsible for maternal and fetal bilirubin conjugation.
6
 However, as fetal 
liver bilirubin conjugation capacity is limited, the fetus relies primarily on maternal hepatic 
bilirubin conjugation to prevent neurotoxic bilirubin exposure to the vulnerable fetal 
brain.
7,8 Neonatal unconjugated bilirubin exposure is associated with adverse neurologic and 
developmental outcomes, including language delays.
9–12 Because maternal ATV 
administration leads to higher maternal unconjugated bilirubin concentrations,
5
 the fetus 
also may be exposed to elevated unconjugated bilirubin levels for a prolonged period.
Combination ART regimens are most effective at preventing mother-to-child 
transmission,
13–15 but concomitant medications affecting maternal ATV pharmacokinetics 
may also affect fetal ATV exposure. Tenofovir disproxil fumarate (TDF) co-administration 
reduces ATV trough concentrations;
16
 similar ATV concentration effects were seen during 
pregnancy with third trimester TDF co-administration.
17
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Intrauterine ATV exposure may affect the fetus directly through transplacental drug transfer 
or indirectly through increased unconjugated bilirubin exposure, thus, accurate fetal ATV 
exposure quantification is critical to understanding infant and child outcomes. Previous fetal 
drug exposure research from terminated pregnancies demonstrated meconium, the first 
neonatal feces, begins to form early in the second trimester,
18,19 with meconium drug 
concentrations reflecting drug exposure during the third and perhaps second trimester.
20,21 
We recently developed a novel meconium ARV drug assay enabling quantitative in utero 
ARV exposure assessment.
22
 As previous studies reported associations between infant 
language development and intrauterine ATV exposure, we sought to quantify ARV 
meconium concentrations and investigate associations between ATV meconium 
concentrations, infant language measures, and maternal ATV medication history.
METHODS
Participants
The prospective PHACS Surveillance Monitoring of ART Toxicities (SMARTT) study 
enrolls pregnant women with HIV and their infants at 22 US sites to evaluate long-term 
prenatal ART exposure effects.
25
 Infants enrolled between 22 weeks gestation and 1 week 
postnatal were included. Each site’s Institutional Review Board approved the study and 
written informed consent was obtained. ARV exposure information, including start and stop 
dates, was abstracted from medical charts.
Meconium ARV quantification
Meconium was collected within 72 hours. Beginning in 2011, meconium was frozen 
immediately after collection; prior to 2011, meconium was refrigerated at study sites. 
Storage conditions were changed to ensure accurate analysis of alcohol use markers; unlike 
these other markers, meconium ATV concentrations proved equally stable under refrigerated 
and frozen conditions. Therefore, meconium ATV concentrations from both storage 
conditions were included. After laboratory receipt, all specimens were frozen (≤−20°C) until 
analysis (0–6 years). Meconium ARV drugs were quantified by our validated liquid 
chromatography tandem mass spectrometry method.
22
 Sixteen parent ARVs and four 
metabolites were quantified in 0.25 g meconium with 10–500 ng/g quantification limits.
22 






 Language domain provides an age-referenced, standardized measure of 
language development from 1–42 months (mean score, SD; 100 ±15). The MacArthur-Bates 
Communicative Development Inventory (CDI)
4
 provides gender-specific, age-adjusted 
percentile scores in four domains: Phrases Understood, Vocabulary Comprehension, Word 
Production, and Total Gestures. Validity of each Bayley-III assessment was determined by 
local examining psychologists; when needed, assessment results were reviewed by a study 
team member to resolve questions. When several CDI questionnaire items were omitted, 
scores were reviewed by a study team language expert. Both measures were administered at 
9–15 months (the one-year study visit). Bayley-III scales were administered directly to 
Himes et al. Page 3













infants; the CDI was administered as a parent/caregiver interview utilizing the age-
appropriate CDI Words and Gestures form. The Bayley-III is available only in English, 
while the CDI is available in English and Spanish. For this study, LLE was defined as a CDI 
score ≤10th percentile in one or more of the four domains.
Statistical analyses
ATV meconium concentration and language outcome distributions were inspected and 
appropriate transformations performed to achieve approximate normal distributions. 
Spearman correlations (ρ) of meconium ATV concentration with ATV exposure duration and 
timing were calculated. Infants whose mothers had interrupted ATV use during pregnancy 
(>three day gap between two regimens or stopped ATV use before delivery) were excluded 
from certain analyses, since maternal time off ATV can affect meconium drug 
concentrations. ATV meconium concentrations from infants whose mothers stopped ATV 
use before delivery were compared separately to those with uninterrupted intrauterine ATV 
exposure with the Wilcoxon rank sum test. A Jonckheere-Terpstra test assessed the trend 
between ATV meconium concentration and prenatal ATV exposure timing.
General linear and logistic regression models were built for continuous and binary language 
measures, respectively. Univariable analyses first identified potential confounders. For each 
outcome, a core model was obtained by identifying covariates associated with the outcome 
with P<0.20 in univariable models and retained with P<0.10 in multivariable models. 
Additionally, when an ATV exposure was added to the model, covariates not included 
initially were evaluated and those that changed ATV exposure estimates by at least 10% and 
were associated with the outcome (P<0.10) were included. Multivariable models were then 
built to estimate associations of adjusted ATV exposure with language outcomes, controlling 
for all identified covariates. Concomitant TDF was forced in multivariable models a priori. 
Maternal and infant characteristics evaluated as potential covariates are described in Table 1. 
Maternal CD4 and HIV RNA during pregnancy were excluded from adjusted models; most 
measurements were obtained after ATV initiation and therefore, we cannot control for 
medical reasons that may have indicated why a mother started ATV. These measurements 
could potentially be confounders or intermediates on the causal pathway between ATV 
exposure and language outcomes.
To evaluate maternal concomitant TDF impact on meconium ATV concentrations, we 
compared ATV concentrations from infants exposed to uninterrupted TDF+ATV+ritonavir 
to those from infants exposed to uninterrupted ATV+ritonavir with Wilcoxon’s rank sum 
test. Group language measures were compared by a two-sample t-test or Fisher’s exact test, 
as appropriate.
Sensitivity analyses evaluated the impact of adjusting for premature birth and low birth 
weight, covariates possibly on the causal pathway between ATV exposure and language 
outcomes.
23
 Sensitivity analyses also adjusted for research site differences, using 
generalized estimating equations models considering individual language evaluations within 
sites as repeated measures. Unpaired t-tests, chi-square tests, and Fisher’s exact test 
compared language scores and neonatal prophylaxis with previously published samples.
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Of 1817 SMARTT Dynamic cohort infants enrolled through January 1, 2014, 432 (24%) 
were exposed to ATV during pregnancy. Meconium specimens were available for ARV 
quantification from 175 of these infants. Supplemental Table 1 compares maternal and infant 
demographic characteristics between these 175 and the other 257 infants. Demographic 
characteristics were similar between groups with a few exceptions; infants with meconium 
ATV results were less likely to be Black, preterm, have low birth weight or caregivers with 
English as their primary language, and they were more likely to have longer cumulative ATV 
exposure durations. Of our 175 ATV-exposed infants with meconium available, 93 had valid 
Bayley-III language scores, and 106 had valid CDI scores. Table 1 shows our study samples’ 
maternal and infant demographic characteristics. The percentage of mothers with viral 
suppression (HIV RNA ≤400 copies/mL) increased from 48–53% at the earliest to 84–86% 
at the latest measure in pregnancy, while the percentage with CD4 ≥350 cells/mm3 showed 
smaller increases from 70–72% at the earliest to 75–79% at later measures. Maternal 
substance use in pregnancy was similar to SMARTT overall.
24
 Most infants in our analysis 
were born in 2010 or 2011. No infant demonstrated hearing loss, based on hearing screening 
or caregiver report.
Of the 175 meconium specimens with ARV quantification, 166 infants had uninterrupted 
ATV exposure (≤three day gap) in the second and third trimesters. Five mothers 
discontinued ATV before delivery; their infants’ meconium ATV concentrations were 
considered separately when uninterrupted exposure was required. Four mothers had a >three 
day interruption in their ATV-containing regimen during the second or third trimester but 
returned to an ATV regimen pre-delivery; these infants were excluded from all analyses 
requiring uninterrupted exposure.
Maternal ATV duration and meconium ATV
Median (range) meconium ATV concentration in the 166 infants with uninterrupted second 
and third trimester ATV exposure was 16,929 ng/g (29–143,018). Many women were on 
ATV throughout pregnancy; median (range) uninterrupted ATV exposure duration, 
excluding first trimester ATV administration, was 24 weeks (2.6–28.1). Uninterrupted ATV 
exposure duration was positively correlated with ATV meconium concentrations (ρ=0.230, 
P=0.003).
Maternal ATV initiation and meconium ATV
Most women using ATV during pregnancy started ATV before pregnancy or in the first 
trimester. Gestational ATV initiation week for women who started ATV before pregnancy or 
in the first trimester was left-truncated to exclude the first trimester and set to 14.1 weeks, as 
meconium only begins to form at the beginning of the second trimester. Median (range) 
ATV initiation week during pregnancy was 14.1 (14.1–35.7). Meconium ATV 
concentrations were grouped by ATV initiation week (in or before early second trimester, 
≤21 weeks; in late second, 21.1–28 weeks; early third, 28.1–34 weeks, or late third trimester, 
34.1–42 weeks), revealing a trend toward decreasing median ATV meconium concentrations 
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with later maternal ATV initiation (P=0.07, Table 2). ATV initiation week negatively 
correlated with ATV meconium concentration (ρ=−0.215, P=0.01).
Five infants whose mothers discontinued ATV-containing regimens before delivery had 
significantly lower ATV meconium concentrations than the 166 infants whose mothers 
remained on ATV through delivery (P<0.001). These five mothers discontinued ATV 19–64 
days before delivery, their ATV duration prior to cessation ranged from 4.1–21.6 weeks, and 
infant meconium ATV concentrations were 102–3,468 ng/g. These five infants’ gestational 
ages at birth were 37–40 weeks and at the time ATV was discontinued, 28.9–35.3 weeks.
Language measures and meconium ATV concentrations
Among the 93 infants with Bayley-III data, the median (interquartile range) Language 
composite score was 94 (86–97) and ATV meconium concentrations ranged from 48–78,963 
ng/g. Infant’s cumulative ATV exposure duration, over the entire pregnancy, ranged from 
4.1–42 weeks. Higher Bayley-III language scores were associated with longer cumulative 
ATV exposure duration (Supplemental Table 2 and Table 3). Meconium ATV concentrations 
were not associated with Bayley-III Language scores in unadjusted or adjusted models; 
additionally, mean Bayley-III scores were not significantly different between infants with the 
lowest (≤10th percentile) and highest (>90th percentile) ATV meconium concentrations.
Among the 106 infants with CDI data, median (interquartile range) percentile scores were 
Vocabulary Comprehension, 45 (20–70); Word Production, 50 (33–60); Phrases Understood 
60 (35–75); Total Gestures, 52.5 (30–70); and mean CDI percentile scores across all 
domains, 50 (34.8–63.8). ATV meconium concentrations ranged from 48–85,166 ng/g and 
cumulative ATV duration from 4.1–41.6 weeks. Higher CDI Phrases Understood scores 
were associated with longer ATV durations, both for cumulative and uninterrupted ATV 
duration measures (Table 3). Meconium ATV concentrations were not associated with 
individual CDI domains or average CDI percentile scores (Supplemental Table 2 and Table 
3). Mean CDI scores were not significantly different between infants with the lowest and 
highest decile ATV meconium concentrations.
Most (92%) CDI-evaluated infants received zidovudine-only neonatal prophylaxis; eight 
infants received zidovudine with other drugs (nevirapine, stavudine, or lamivudine
+stavudine+nevirapine). Prophylaxis duration ranged from 1–66 days. There was no 
difference in the proportion of infants who received combination prophylaxis among those 
with LLE risk (4/25) and those without LLE risk (4/81, P=0.09); additionally, neonatal 
prophylaxis duration was not significantly different between the two groups.
Maternal concomitant ART medication
Most mothers (77% of the 166 with uninterrupted ATV exposure) were on a TDF-containing 
ATV regimen. Three infants exposed to other ATV regimens were excluded from this 
comparison. Figure 1 illustrates group differences by uninterrupted ATV exposure duration. 
Spearman correlations between ATV exposure duration and meconium concentration were 
ρ=0.212, P=0.01 overall; ρ=0.199, P=0.03 for TDF+ATV+ritonavir; and ρ=0.343, P=0.03 
for ATV+ritonavir (Figure 1). Bayley-III and CDI scores and LLE risk prevalence were not 
significantly different between infants exposed to TDF+ATV+ritonavir and ATV+ritonavir. 
Himes et al. Page 6













The most prevalent maternal combination ART regimen in our sample was TDF
+emtricitabine+ritonavir+ATV followed by zidovudine+lamivudine+ritonavir+ATV.
Sensitivity analyses
Similar results as the primary analyses were observed from sensitivity analyses. Adjusting 
for preterm birth and low birth weight, or accounting for within-site correlations, did not 
change the associations except significant associations of cumulative ATV exposure duration 
with Bayley-III language and CDI Phrases Understood scores were attenuated after 
accounting for differences within sites.
Sample comparisons
Mean Bayley-III Language scores obtained in this study (93.2 ± 10.7) were lower than mean 
scores from the Bayley-III standardization sample
25
 (P<0.001). Infants in our study also had 
significantly higher mean Bayley-III Language scores, higher CDI Total Gestures percentile 
scores, and lower LLE risk incidence compared to those in previously published SMARTT 
studies,
3,4 excluding infants who contributed data to both (Bayley-III, n=16; CDI, n=30). 
The mean Bayley-III Language score from our unique infant cohort (n=77) was 93.1 (±10.7) 
compared to the mean, 88.8 (±14.2), of unique infants with ATV exposure (n=62) in the 
previously published cohort (P=0.04). Our unique CDI-evaluated cohort (n=76) obtained a 
higher Total Gestures domain percentile score compared to those in the previous report (53 
versus 35, P=0.02); otherwise, there were no differences between cohorts across CDI 
domains. LLE risk incidence among infants with ATV exposure in our sample was lower 
than in the previous report (22% versus 37%, P=0.05).
4
 Proportion of infants who received 
combination neonatal prophylaxis and duration of this treatment among those with and 




In utero HIV exposure was previously associated with increased language impairment risk 
among 7–16 year-olds with prenatal HIV exposure (HIV-infected, 51%; HEU, 37%) 
compared to the general US population (16%).
26
 Associations at one year of age between 
prenatal ATV exposure, lower Bayley-III Language scores,
3
 and elevated LLE risk
4
 also 
were identified. As ATV use during pregnancy becomes more widespread,
1,2 these 
associations warrant further monitoring.
In this investigation, longer ATV exposure durations were associated with higher ATV 
meconium concentrations, which were protective against LLE risk. Confirming this 
association was our finding that longer cumulative ATV exposure durations resulted in 
higher Bayley-III Language scores. These results differ from two previous SMARTT 
reports,
3,4 possibly due to sampling differences associated with small samples or random 
variability. There was minimal overlap between the three studies’ samples; only 30 of our 
106 CDI-evaluated infants and 16 of our 93 Bayley-evaluated infants were included in 
previous SMARTT studies. Infants in our study also had lower LLE risk and higher Bayley-
III Language scores compared to those in our previous research; these improved outcomes 
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may have challenged confirmation of previous negative ATV exposure associations, or may 
be causative for the decreased LLE risk observed here compared to the previously seen 
increased LLE risk. Additionally, our results confirm previous PHACS research that showed 
increased LLE risk among HEU children; 24–42% of HEU children in our study and 
previous PHACS studies
4, 26 demonstrated risk of LLE or language impairment, compared 
to an expected prevalence of 16–20% among children in the general population.
26
Changing ARV use during pregnancy trends, random sampling differences, and cohort 
effects may have contributed to differences among the studies. Healthier women are 
receiving ATV more often now than in previous years; additionally, pregnant women with 
HIV may be healthier now due to continuous use of well-tolerated medications with lower 
pill burdens.
1,2 Most infants included in this investigation were born later than infants in the 
previous SMARTT analyses; 78% of infants in the current study with Bayley-III data and 
59% with CDI data were born after the earlier analyses’ cutoff dates (5/1/2009 and 4/1/2010, 
respectively).
3,4 Further investigations must clarify these different results; however, the 
present findings confirm ATV exposure safety on infant language development, which 
supports the 2014 HHS recommendations
1
 of ritonavir-boosted ATV as a preferred ART 
regimen for pregnant women with HIV. Further study also should determine if associations 
remain consistent as children age.
A potential mechanism for our observed lowered LLE risk may be ATV clearance into 
meconium. Higher ATV meconium concentrations are likely an indication of fetal ATV 
detoxification. ATV is primarily eliminated via hepatic pathways.
27
 In adults, ATV is 
metabolized by CYP3A4 and CYP3A5,
28,29 mainly by oxidation, although several 
metabolites and metabolic pathways are known.
30,31 ATV metabolism varies widely as 
adults on steady-state ritonavir-boosted ATV showed cumulative metabolite concentrations 
from 4–32% of parent ATV concentrations.
31
 Fetal ATV metabolism and clearance are 
unknown; however, published fetal liver CYP3A studies indicate fetal ATV metabolism is 
limited. Fetal CYP3A4 content and activity is <10% of adult levels,
32–34 and little is known 
about fetal CYP3A5 activity.
33,34 CYP3A7 accounts for 87–100% of total fetal liver CYP3A 
content, and shows high catalytic activity toward endogenous steroids but lower activity 
towards exogenous substances, traditional CYP3A4 substrates.
35,36 Our data suggest a 
potential mechanism for the lowered LLE risk via fetal ATV clearance capacity, although 
ATV clearance to meconium also may be affected by maternal and infant factors not 
investigated in this study.
Associations between infant meconium ATV concentrations, uninterrupted second and third 
trimester ATV exposure duration, and gestational ATV initiation week were significant. 
Meconium drug concentrations can be influenced by variations in maternal dosage, fetal 
exposure duration and timing, placental transfer, and maternal and fetal pharmacokinetics 
and metabolism. Our significant observations and wide ATV meconium concentration range 
among women with uninterrupted ATV exposure (29–143,018 ng/g) demonstrate the 
significance of these influencing factors.
Three potentially reactive CYP3A4-generated ATV metabolites (an aromatic aldehyde, 
alpha-hydroxyaldehyde, and hydrazine metabolite) were recently identified in human liver 
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 Oral ATV administration to mice, however, produced no 
detectable urinary or fecal concentrations of these metabolites.
37
 Potential metabolite 
toxicity is not yet known, though similar chemical structures are associated with glutathione 
and protein adducts, hepatic lesions, and neurotoxicity.
37–39 Initially, we hypothesized 
higher ATV meconium concentrations might indicate greater fetal exposure and therefore, 
predict lower language scores and higher LLE risk. Our findings now suggest higher ATV 
meconium concentrations likely indicate greater fetal ATV detoxification as there is less 
ATV available to form potentially toxic metabolites and hence better language outcomes. 
Additionally, lower ATV meconium concentrations suggest reduced ATV clearance, likely 
associated with higher fetal plasma ATV or metabolite concentrations throughout pregnancy, 
which might be correlated with increased LLE risk. Human plasma and meconium 
metabolite concentrations should be investigated, although commercial standards are 
currently unavailable. Further study into these metabolites’ clinical implications is needed. 
However, as ritonavir is commonly co-administered, the in vitro metabolite study failed to 
investigate ritonavir’s reduction of potentially toxic ATV metabolite formation, as seen with 
lopinavir.
40
Associations between infant meconium ATV concentrations, uninterrupted second and third 
trimester ATV exposure duration, and gestational ATV initiation week were significant. 
Longer ATV exposure periods correlated with higher ATV meconium concentrations, and 
later ATV initiation resulted in lower ATV meconium concentrations. These correlations 
were weak (ρ< ±0.25), suggesting meconium ATV concentrations do not predict and only 
partially reflect maternal ATV duration or initiation timing.
TDF addition to a mother’s ritonavir-boosted ATV therapy resulted in a decreasing 
meconium ATV concentration trend, as predicted from previous pharmacokinetic studies.
17 
However, no group language differences were observed between infants exposed to 
ritonavir-boosted ATV regimens with and without TDF.
While our investigation was unique, it was limited by lack of information about neonatal and 
maternal bilirubin concentrations, maternal UGT1A1 polymorphisms, and infant 
phototherapy. Future studies could employ these additional tests to better understand factors 
contributing to ATV’s impact on infant language development. Further investigation of 
pathophysiological and psychosocial influences on HEU infant language development is 
needed to develop targeted interventions to address potential language delays. Previous 
research indicated socioeconomic factors, genetic influences, and maternal HIV disease 
status may affect language acquisition.
4, 26, 41
ATV meconium quantification provided a novel in utero ATV exposure assessment, and for 
the first time, demonstrated the value of including meconium ARV concentrations in 
longitudinal research on HIV. Higher meconium ATV concentrations were protective of LLE 
risk. Clinically, this information supports ATV safety during pregnancy for infant language 
development. Additionally, higher ATV meconium concentrations observed in our study 
may indicate greater fetal ATV detoxification as these concentrations protected against LLE 
risk. With ATV now a preferred ARV for pregnant women with HIV, our data add evidence 
to fetal ATV exposure safety for language development. Our ATV meconium research 
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findings will be helpful to medical professionals evaluating in utero ATV exposure safety for 
infant language development.
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Meconium ATV concentration by uninterrupted ATV exposure duration (from gestational 
week 14 through delivery) for infants exposed to TDF+ATV+ritonavir (n=125, astericks) 
and ATV+ritonavir (n=38, open circles). Exposure duration was determined by excluding 
first trimester ATV exposure (0–14 weeks), as meconium only begins to form at the 
beginning of the second trimester. Spearman correlations between ATV exposure duration 
and meconium concentration were ρ=0.212, P=0.01 overall; ρ=0.199, P=0.03 for TDF+ATV
+ritonavir; and ρ=0.343, P=0.03 for ATV+ritonavir.
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Table 1
Maternal, caregiver, and infant demographic characteristics among atazanavir (ATV)-exposed infants with 
meconium antiretroviral (ARV) quantification and completed language evaluations
Characteristic Bayley-III(n=93); n (%)
CDI
(n=106); n (%)
Maternal age at delivery ≥ 35 years 19 (20%) 21 (20%)
Tobacco use during pregnancy 16 (17%) 18 (17%)
Alcohol use during pregnancy 8 (9%) 10 (9%)
Illicit drug use during pregnancy 9 (10%) 9 (8%)
First absolute CD4 (cells/mm3) during pregnancya < 200 11 (12%) 12 (11%)
≥ 350 65 (70%) 76 (72%)
Last absolute CD4 (cells/mm3) before deliverya < 200 8 (9%) 8 (8%)
≥ 350 70 (75%) 84 (79%)
First RNA (copies/mL) during pregnancy ≤ 400 45 (48%) 56 (53%)
> 1000 42 (45%) 44 (42%)
Last RNA (copies/mL) before delivery ≤ 400 78 (84%) 91 (86%)
> 1000 14 (15%) 14 (13%)
Concomitant TDF use with ATV regimen 79 (85%) 85 (80%)
Caregiver primary language English 66 (71%) 67 (63%)
English bilingual 21 (23%) 20 (19%)
Spanish 4 (4%) 18 (17%)
Other 2 (2%) 1 (1%)
Household annual income ≤ $10,000b 50 (54%) 57 (54%)
Caregiver education < high school 35 (38%) 37 (35%)
Live with partner/spouse 47 (51%) 59 (56%)
Sexually transmitted disease during pregnancy 45 (48%) 48 (45%)
Caregiver IQc Median (range) 85 (58–115) 85 (58–115)
Caregiver IQc < 85 37 (40%) 35 (33%)
Caregiver: positive screen for any postpartum psychiatric syndromed 27 (29%) 31 (29%)
Caregiver: positive screen for postpartum alcohol abused 2 (2%) 2 (2%)
Caregiver: positive screen for postpartum drug abused 3 (3%) 3 (3%)
Infant age (months) at time of language evaluation Median (range) 13.0 (11.7 – 19.8) 12.8 (11.7 – 23.4)
Language evaluation version English 93 (100%) 84 (79%)
Spanish Not applicable 22 (21%)
Infant sex Male 54 (58%) 60 (57%)
Infant race Black 73 (78%) 70 (66%)
Puerto Rican Not applicable 6 (6%)
Caucasian/Other 20 (22%) 30 (28%)
Infant Hispanic ethnicity 20 (22%) 37 (35%)
Gestational age (weeks) Median (range) 38.6 (33.0 – 41.9) 38.6 (33.0 – 41.4)
Preterm (< 37 weeks gestation) 10 (11%) 10 (9%)
Low birth weight (< 2500 g) 7 (8%) 8 (8%)
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Characteristic Bayley-III(n=93); n (%)
CDI
(n=106); n (%)
Small for gestational age (< 10th percentile for gestational age) 5 (5%) 6 (6%)
Infant birth year 2007 3 (3%) 3 (3%)
2008 13 (14%) 15 (14%)
2009 13 (14%) 18 (17%)
2010 22 (24%) 27 (25%)
2011 28 (30%) 29 (27%)
2012 14 (15%) 14 (13%)
Missing data: Bayley-III: maternal first/last CD4 count during pregnancy (n=1, 1%), maternal/caregiver IQ (n=17, 18%), maternal/caregiver 
positive screen for postpartum psychiatric syndrome, alcohol or drug abuse (n=3, 3%), and small for gestational age (n=1, 1%); CDI: household 
annual income (n=1, 1%), sexually transmitted disease during pregnancy (n=1, 1%), maternal/caregiver IQ (n=31, 29%), maternal/caregiver 
positive screen for postpartum psychiatric syndrome or alcohol or drug abuse (n=1, 1%), and small for gestational age (n=1, 1%). Tobacco, alcohol, 
and illicit drug use during pregnancy were determined from maternal self-report and validated through meconium analysis.
24
 Maternal/caregiver 
cognition and maternal/caregiver mental health status were evaluated at the one-year-old study visit with the Wechsler Abbreviated Scale of 
Intelligence
42
 and Client Diagnostic Questionnaire (CDQ),
43
 respectively. CDI indicates the MacArthur-Bates Communicative Developmental 
Index.
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Table 2
Atazanavir (ATV) meconium concentrations by gestational week of ATV initiation
Timing of ATV Exposure n Median (range) ATV meconium concentration (ng/g)a
Early second trimester (≤21 weeks) 130 17,840(99 – 125,352)
Later second trimester (21.1–28 weeks) 24 13,510(29 – 116,000)
Early third trimester (28.1–34 weeks) 10 9,026(139 – 143,018)
Later third trimester (34.1–42 weeks) 2 6,447(443 – 12,450)
a
Jonckheere-Terpstra trend test, P=0.07
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